Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial
AstraZeneca
Hiddo J L Heerspink; Arihiro Kiyosue; David C Wheeler; Min Lin; Emma Wijkmark; Glenn Carlson; Anne-Kristina Mercier; Magnus Åstrand; Sebastian Ueckert; Peter J Greasley; Phil Ambery
Biometrics Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. ; Biometrics Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.